Trial Profile

A phase I trial to compare the administration of OCU500 via two different mucosal routes, inhalation into the lungs and as a nasal spray

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2025 According to Ocugen media release, the Investigational New Drug application is in effect for OCU500, and the National Institute of Allergy and Infectious Diseases intends to initiate a Phase 1 clinical trial in the second quarter of 2025.
27 Jan 2025 According to Ocugen media release, NIAID, with funding from Project NextGen, will cover the full cost of the Phase 1 clinical trial, including operations and related analysis.
27 Jan 2025 According to Ocugen media release, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug (IND) application and it is in effect.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com